Trial Outcomes & Findings for Bridge Occlusion Balloon in Lead Extraction Procedure (NCT NCT02714153)
NCT ID: NCT02714153
Last Updated: 2021-06-14
Results Overview
After Bridge Balloon deployment and inflation, the degree of blood vessel occlusion will be reported. Measurements will be calculated from fluoroscopic images (using x-ray machine) and venograms (images with injection of contrast agent). Successful balloon occlusion of the superior vena cava (SVC) is defined as \>90% occlusion of the SVC by visual estimate using conventional venography.
COMPLETED
NA
23 participants
33 minutes (average time)
2021-06-14
Participant Flow
Participant milestones
| Measure |
Bridge Occlusion Balloon
Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
Bridge Balloon: The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
|
|---|---|
|
Overall Study
STARTED
|
23
|
|
Overall Study
COMPLETED
|
22
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
| Measure |
Bridge Occlusion Balloon
Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
Bridge Balloon: The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
|
|---|---|
|
Overall Study
Death
|
1
|
Baseline Characteristics
Bridge Occlusion Balloon in Lead Extraction Procedure
Baseline characteristics by cohort
| Measure |
Bridge Occlusion Balloon
n=23 Participants
Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
Bridge Balloon: The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
|
|---|---|
|
Age, Continuous
|
61 years
STANDARD_DEVIATION 15 • n=5 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
19 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
23 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
23 participants
n=5 Participants
|
|
Comorbidities
Congenital Heart Disease
|
1 Participants
n=5 Participants
|
|
Comorbidities
Diabetes Mellitus
|
6 Participants
n=5 Participants
|
|
Comorbidities
Coronary Artery Disease
|
11 Participants
n=5 Participants
|
|
New York Heart Association Class
I
|
2 Participants
n=5 Participants
|
|
New York Heart Association Class
II
|
5 Participants
n=5 Participants
|
|
New York Heart Association Class
III
|
13 Participants
n=5 Participants
|
|
New York Heart Association Class
IV
|
3 Participants
n=5 Participants
|
|
Ejection Fraction
|
43 percent
STANDARD_DEVIATION 15 • n=5 Participants
|
|
Creatinine
|
1.05 mg/dL
STANDARD_DEVIATION 0.29 • n=5 Participants
|
PRIMARY outcome
Timeframe: 33 minutes (average time)Population: All patients.
After Bridge Balloon deployment and inflation, the degree of blood vessel occlusion will be reported. Measurements will be calculated from fluoroscopic images (using x-ray machine) and venograms (images with injection of contrast agent). Successful balloon occlusion of the superior vena cava (SVC) is defined as \>90% occlusion of the SVC by visual estimate using conventional venography.
Outcome measures
| Measure |
Bridge Occlusion Balloon
n=23 Participants
Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
Bridge Balloon: The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
|
|---|---|
|
Number of Participants With Successful Balloon Occlusion of Superior Vena Cava
First Balloon Deployment
|
18 Participants
|
|
Number of Participants With Successful Balloon Occlusion of Superior Vena Cava
Reposition and Reinflation
|
5 Participants
|
SECONDARY outcome
Timeframe: 33 minutes (average time)Population: All patients.
Time will be calculated in seconds starting from opening the Bridge Balloon Package up to full balloon deployment.
Outcome measures
| Measure |
Bridge Occlusion Balloon
n=23 Participants
Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
Bridge Balloon: The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
|
|---|---|
|
Time of Bridge Balloon Deployment
|
121 seconds
Standard Deviation 50
|
SECONDARY outcome
Timeframe: 1 yearPopulation: All patients.
Heart Rate (in beat per minute) will be collected at 5 points: baseline, after guidewire insertion, at the time of balloon inflation, immediately post deflation and 5 minutes post deflation (all during the procedure itself). This outcome will be reported at the end of the study as if there were any unacceptable or no unacceptable changes in the hemodynamics over the course of the 12 month period.
Outcome measures
| Measure |
Bridge Occlusion Balloon
n=23 Participants
Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
Bridge Balloon: The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
|
|---|---|
|
Number of Participants With Changes in Heart Rate at One Year
Unacceptable Changes
|
0 Participants
|
|
Number of Participants With Changes in Heart Rate at One Year
No Unacceptable Changes
|
23 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: All patients.
Blood pressure in mmHg will be collected at 5 points: baseline, after guidewire insertion, at the time of balloon inflation, immediately post deflation and 5 minutes post deflation (all during the procedure itself). This outcome will be reported at the end of the study as as if there were any unacceptable or no unacceptable changes in the hemodynamics over the course of the 12 month period..
Outcome measures
| Measure |
Bridge Occlusion Balloon
n=23 Participants
Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
Bridge Balloon: The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
|
|---|---|
|
Number of Participants With Changes in Blood Pressure at One Year
Unacceptable Changes
|
0 Participants
|
|
Number of Participants With Changes in Blood Pressure at One Year
No Unacceptable Changes
|
23 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: All patients.
SPO2 will be collected at 5 points: baseline, after guidewire insertion, at the time of balloon inflation, immediately post deflation and 5 minutes post deflation (all during the procedure itself). This outcome will be reported at the end of the study as if there were any unacceptable or no unacceptable changes in the hemodynamics over the course of the 12 month period..
Outcome measures
| Measure |
Bridge Occlusion Balloon
n=23 Participants
Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
Bridge Balloon: The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
|
|---|---|
|
Number of Participants With Changes in SPO2 at One Year
Unacceptable Changes
|
0 Participants
|
|
Number of Participants With Changes in SPO2 at One Year
No Unacceptable Changes
|
23 Participants
|
Adverse Events
Bridge Occlusion Balloon
Serious adverse events
| Measure |
Bridge Occlusion Balloon
n=23 participants at risk
Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
Bridge Balloon: The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
|
|---|---|
|
Vascular disorders
SVC Tear
|
4.3%
1/23 • Number of events 1 • 1 year
|
Other adverse events
Adverse event data not reported
Additional Information
Jude Clancy, MD Associate Professor Term; Director, Lead Management Program
Yale School of Medicine
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place